Prolifix Limited

Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis

Agendia N.v.

Rene Bernards

Iris Simon

Paul Roepman

Annuska Maria Glas

Nicholas B La Thangue

Renate M Zwijsen

Roderick L Beijersbergen

Rodrigo Leite De Oliveira

Eleonore M Hijmans

Rob J Michalides

Tian Sun

Guus Hateboer

Liqin Wang

Chong Sun

Lodewyk Frederik Ary Wessels

Magali Michaut

Tycho Bismeijer

The current invention relates to treatment of drug resistant melanoma with histone deacetylase inhibitors (HDACi). In particular the invention relates to BRAF and NRAS mutated melanoma and that have acquired resistance to MAPK pathway inhibitors, for example due to previous treatment with such MAPK pathway inhibitors. The invention discloses HDACi and/or MAPK pathway inhibitors for use in such treatment and treatment regimens using such inhibitors.

Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma

The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of inhibitors of MEK, EGFR and ERBB2 in the treatment of KRAS-mutant lung cancer, and KRAS-mutant colon cancer.

Combinations for treatment of cancer

Two novel transcription factors belonging to the E2F gene family, are disclosed. These are human and murine E2F-5. They can interact with DP-1 and p130.

Transcription factor-E2F-5

Transcription factor E2F-4

Interaction of cyclin D1 and estrogen receptor and its use in assays

Adenovirus E1A-Associated protein BS69, inhibitor of E1A-transactivation

Growing community of inventors

Amsterdam, Netherlands

Rene Bernards